NEW YORK, December 30, 2025, 05:26 ET — Premarket
Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech.
The move matters because Belite is trying to turn a rare-disease eye drug into a first-in-class launch, and the stock is now trading well above the $154 level at which it last sold new shares in a major December offering. In markets where liquidity thins out near year-end, sharp moves can pull in momentum traders fast.
Tuesday’s setup also comes with a news vacuum. Belite’s most recent company statements remain its trio of Dec. 1 releases, including late-stage trial results and two equity-financing announcements.
On Dec. 1, Belite said its oral drug tinlarebant met the main goal in a late-stage study in Stargardt disease type 1, a progressive inherited retinal disorder that can cause vision loss starting in childhood. The company said it plans to file for U.S. approval in the first half of 2026, and noted the condition has no FDA-approved treatments.
Belite’s executives have framed the Phase 3 readout as a turning point. “The DRAGON trial delivers the most compelling evidence to date that an oral therapy can alter the course of Stargardt disease,” said Dr. Hendrik Scholl, the company’s chief medical officer, in the Dec. 1 statement. GlobeNewswire
The same day, Belite said it priced an underwritten public offering of 2,272,727 American depositary shares at $154 per ADS, targeting about $350 million in gross proceeds. ADSs are U.S.-traded certificates that represent shares of a non-U.S. company; Belite said it planned to use the funds to prepare for commercialization, expand its pipeline and for general corporate purposes.
After the regular-session surge, the stock was last quoted around $165 in late Monday trading, little changed from the close.
With no new filings or clinical updates flagged since Dec. 1, traders are watching whether Monday’s jump holds once regular trading begins. The $170 area is the immediate reference point after the stock’s intraday spike.
The next fundamental catalyst is timing clarity. Investors want firmer detail on the path from the Phase 3 data package to a U.S. submission, and what post-trial analyses or medical-meeting presentations might add to the story.
